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Background: The aim of this study was to investigate how Ser31Arg polymorphisms in p21 may 
modify lung cancer susceptibility. Because p21 is the major downstream mediator of p53, we 
analyzed the combined effect of two polymorphisms, p21 Ser31Arg and TP53 Arg72Pro, to 
elucidate whether polymorphic variants determine the risk of lung cancer.
Methods: This was designed as a hospital-based case-control study, and included 675 cases 
and 675 control subjects matched by ethnicity, gender, and age. Genotypes were determined 
by polymerase chain reaction restriction fragment length polymorphism, and multivariate 
unconditional logistic regression was performed to analyze the results.
Results: Subjects who carried the p21 Ser31Arg allele had a higher risk of lung cancer (adjusted 
odds ratio [OR] 1.38; 95% confidence interval [CI] 0.99–2.03). This risk was increased in men 
aged younger than 55 years (adjusted OR 2.35; 95% CI 1.00–5.51). Smokers had an increased 
risk of lung cancer (adjusted OR 2.23; 95% CI 1.24–4.02). Men younger than 55 years carrying 
risk alleles for both genes (p21 Ser31Arg and TP53 Arg72Pro) had an increased risk (adjusted 
OR 5.78; 95% CI 1.38–24.19), as did smokers with both risk alleles (adjusted OR 4.52; 95% 
CI 1.52–13.50).
Conclusion: The presence of both variant alleles increased the risk of developing lung cancer 
in men, particularly in smokers younger than 55 years.
Keywords: molecular epidemiology, cell cycle, tobacco, susceptibility, oncology
Introduction
In Spain, 20,401 deaths were caused by lung cancer in 2009. In men, lung cancer is 
the second most common cause of death (17,279 deaths in 2009) and the death rate in 
women is currently rising (3122 deaths in 2009).1 Factors such as genetic susceptibility,2 
occupation, air pollution, and diet are thought to be involved in individual variations 
in lung cancer risk. Several studies have demonstrated that genetic polymorphisms 
such as p53 Arg72Pro,3 occupational exposure to carcinogens,4 and air pollution are 
linked to a higher prevalence of lung cancer.5 In addition, consumption of fruit and 
vegetables6,7 and physical activity may be protective against lung cancer.8 The impor-
tance of genetic susceptibility and its relationship with development of cancer has 
also been widely studied.2,3,5,9,10
p21 is a cyclin-dependent kinase inhibitor, and is important for regulating the 
cell cycle and controlling cells in the G1 phase. The tumor suppressor gene TP53 
expresses p53 protein that tightly controls p21 gene expression, and can block the cell 
cycle in response to a wide range of stressor stimuli. By interacting with proliferating 
cell nuclear antigen, p21 takes part in replication and DNA repair in the S phase of 
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the cell cycle.11,12 This promotes cell differentiation and inhi-
bition of cellular senescence. As well as its role in cell cycle 
control, p21 is involved in DNA repair, such as nucleotide 
excision and base excision repair.13–16
At least 40 polymorphisms have been described for p21, 
of which only seven have a frequency higher than 10%. One 
of these polymorphisms, sited in codon 31, results in an amino 
acid exchange of serine to arginine, causing a cytosine to 
adenine conversion. The polymorphism is located in a highly 
conserved region, which includes a zinc finger. Because this 
region is involved in the molecular activity of p21, its cell 
cycle functions could be affected by the polymorphism.17 
Despite extensive investigation, the potential role of 
p21 polymorphisms in lung cancer remains unclear.18–20
Because p21 is regulated by the p53 tumor suppressor, and 
both have important roles in cell cycle regulation, we studied 
how polymorphisms of these genes may affect the risk of lung 
cancer, as a continuation of our previous study demonstrating 
a correlation between p53 Arg72Pro polymorphisms and risk 
of lung cancer.3 The objective of this study was to examine 
the p21 Ser31Arg and p53 Pro72Arg polymorphisms in 675 
lung cancer cases and 675 selected controls recruited for a 
hospital-based case-control study to elucidate whether the 
polymorphic variants determine the risk of lung cancer.
Materials and methods
Study population
CAPUA (Lung Cancer in Asturias [Cáncer de Pulmón en 
Asturias], Spain) is a hospital-based case-control study. 
Detailed methods of how participants were recruited for this 
study have been described elsewhere.2,3,5,9,10 Briefly, histological 
analysis identified lung cancer cases that were recruited from 
two main hospitals in Asturias in Northern Spain (Cabueñes 
Hospital in Gijón and San Agustin Hospital in Avilés) 
from October 2000 to June 2010, following an identical 
protocol. Controls were selected from patients admitted to 
the participating hospitals for disorders or diseases believed 
to be unrelated to lung cancer. The controls were individually 
matched to the cases on the basis of ethnicity, gender, and age 
(±5 years). The final controls selected showed the following 
main specific pathologies: appendicitis (ICD-9 540; 8.8%), 
intestinal obstruction (ICD-9 560, 569, 574; 13.3%), injury 
(ICD-9 800–848, 860–869, 880–897; 32.5%), and inguinal 
or abdominal hernia (ICD-9 550–553; 41.1%). The ethical 
committees of the hospitals where recruitment took place 
approved the study, and written consent was obtained from 
each participant. In total, 879 cases and 803 controls agreed to 
participate in the study and were subsequently interviewed. Of 
these, 841 cases (95.7%) and 742 controls (92.4%) provided 
a blood or buccal cell sample. Finally, 675 cases and 675 
controls were available for the study after DNA extraction, 
genotyping, and matching cases and controls.
Data collection
Trained interviewers used computer-assisted questionnaires 
to collect information on known or potential risk factors for 
lung cancer during the first hospital admission for diagnosis. 
Structured questionnaires included information on age, 
gender, sociodemographic characteristics, diet (including 
alcohol consumption), tobacco use (both recent and prior), 
and personal and family history of cancer (first-degree 
relatives). All eligible cases and controls included in our 
analysis were Caucasian.
For tobacco consumption, participants were grouped 
into three categories: never smokers (subjects who had not 
smoked at least one cigarette per day regularly for 6 months 
or longer in their lifetimes); former smokers (regular smokers 
who had stopped smoking at least one year before the 
interview); and current smokers (subjects who met none of 
the previous criteria). Smoking intensity (pack-years) was 
defined as the number of packs of cigarettes smoked per day 
multiplied by the number of years of smoking. Information 
about work status was classified according to list A and list B, 
and both lists were translated into codes of the International 
Standard Classification of Occupations and the International 
Standard Industrial Classification.21,22
Genotype analysis
Laboratory personnel were blinded to the case or control 
status of subjects. Peripheral blood samples (96.5% of 
total) or exfoliated buccal cells (3.5% of total) were used 
to extract genomic DNA, as previously described.23 To 
determine p21 Ser31Arg polymorphism (rs 1801270), 
exon 3 of the p21 gene was amplified by polymerase 
chain reaction (PCR) using the following primers: for-
ward primer 5′-CCCGGCCAGGTAACATAGTG-3′ and 
5′-AACTCGAAGTTCCATCGCTC-3′ as the reverse 
primer. PCR was performed in a 10 µL mixture containing 
20 ng of genomic DNA, 0.25 mM each dNTP, 0.5 units of 
Taq polymerase (Biotools, Madrid, Spain) and 10 pmol of 
each primer in 1 × PCR buffer. The PCR running conditions 
were 5 minutes at 94°C followed by 30 cycles of 30 seconds 
at 94°C, 30 seconds at 62°C, and 30 seconds at 72°C, with 
a final step at 72°C for 7 minutes. After being digested 
overnight with BlpI at 37°C, DNA fragments were resolved 
on 1.5% agarose gel and stained with ethidium bromide. 
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After electrophoresis, homozygous Ser/Ser was represented 
by two DNA bands of 159 base pairs and 70 base pairs, the 
homozygous Arg/Arg genotype was represented by a 229 
band of base pairs, and the heterozygous (Ser/Arg) genotype 
was represented by a combination of three bands (229, 159, 
and 70 base pairs). Genotype analysis of p53 Arg72Pro has 
been described eslewehere.3
Statistical analysis
Observed genotype frequencies and a χ2 test with one degree 
of freedom were used to test for Hardy-Weinberg equilib-
rium among the controls. In order to compare the distribu-
tion of age and gender and the frequencies of alleles and 
genotypes, univariate analysis was performed. Differences 
in the distribution between cases and controls were tested 
using the χ2, Fisher’s Exact, and Mann–Whitney U tests 
where appropriate. Wolf’s method was used to calculate the 
crude odd ratios (OR).24 Multivariate unconditional logistic 
regression analysis with adjustment for age, gender, occupa-
tion (list A), and smoking status was performed to calculate 
the adjusted OR and 95% confidence intervals (CI). Gene-
environment interactions were estimated using the logistic 
regression model, which included an interaction term as well 
as variables for exposure (smoking, occupation), genotypes 
(p53 and p21), and potential confounders (age and gender). 
All statistical analyses were performed with Stata version 
8 software (Statacorp, College Station, TX).
Results
Subject characteristics
In this study, the analysis included 675 lung cancer cases 
and 675 controls. The distribution of gender, age, smoking 
status, pack-years, occupation (list A), and histological type 
for cases among the study subjects was assessed (Table 1A). 
The mean age of the subjects was 64.14 years in controls 
and 65.26 years in lung cancer cases. The main histologi-
cal types were squamous cell carcinoma (40.72%), adeno-
carcinoma (30.09%), and small cell carcinoma (17.07%). 
Histological distribution varied according to gender: for 
men, the most common histological type was squamous 
cell carcinoma (43.29%), while adenocarcinoma was the 
main histological type for women (54.43%, Table 1B). In 
our population, the mean pack-year tobacco consumption 
was 61.95 in cases and 36.16 in controls. We determined the 
genotype distribution of the Ser31Arg polymorphism in p21 
and analyzed the risk of lung cancer for the combined effect 
of the Ser31Arg polymorphism in p21 and the Arg72Pro 
polymorphism in p53.
Analysis of p21 Ser31Arg and 
p53 Arg72Pro polymorphisms
First, we investigated distribution of the Ser31Arg 
polymorphism. Because of the low risk of homozygous geno-
type frequency Arg/Arg, we placed all Arg carriers (homozygous 
and heterozygous) into one group. p21 Arg allele frequency was 
0.08 in cases and 0.07 in controls. The frequency of Arg carriers 
was 16.08 in cases and 13.09 in controls (Table 2). Ser31Arg 
polymorphisms were in Hardy-Weinberg equilibrium in our 
control population (χ2 HW = 0.29; P = 0.589).
Table 1A Characteristics of lung cancer cases and control patients
Variable Cases  
(n = 675) 
n (%)
Controls  
(n = 675) 
n (%)
Pa
Gender
Male 595 (88.15) 595 (88.15)
Female 80 (11.85) 80 (11.85) 1.000
Age (years), mean (SD) 65.26 (10.98) 64.14 (11.2) 0.064
Pack-years, mean (SD) 61.95 (36.16) 36.32 (31.13) ,0.001
,37 139 (20.62) 294 (43.68)
$37 490 (72.70) 191 (28.38) ,0.001
Family history of cancer
No 366 (56.92) 400 (60.06)
Yes (any cancer) 277 (43.08) 266 (39.94) 0.249
Lung cancer 76 (11.82) 45 (6.76) 0.007
Other cancer 201 (31.26) 221 (33.18)
Missing 32 9
Histological type
Squamous cell carcinoma 272 (40.72)
Adenocarcinoma 201 (30.09)
Small cell carcinoma 114 (17.07)
Nondifferentiated 43 (6.44)
Large cell carcinoma 22 (3.29)
Others 10 (1.50)
Clinical diagnosis 6 (0.90)
Missing 7
List A, mean (SD)
Yes 129 (19.79) 94 (14.48)
No 523 (80.21) 555 (85.52) 0.011
Missing 23 26
Years in list A, mean (SD) 17.45 (14.59) 15.88 (13.89) 0.418
Missing 23 26
Note: aTwo-sided χ2 test and Mann–Whitney test when appropriate.
Abbreviation: SD, standard deviation.
Table 1B Histological distribution of population by gender
Histological type Men Women
Squamous cell carcinoma 255 (43.29) 17 (21.52)
Adenocarcinoma 158 (26.83) 43 (54.43)
Small cell carcinoma 101 (17.15) 13 (16.46)
Nondifferentiated 40 (6.79) 3 (3.80)
Large cell carcinoma 20 (3.40) 2 (2.53)
Others 10 (1.70) 0 (0.00)
Clinical diagnosis 5 (0.85) 1 (1.27)
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Analysis of the Ser31Arg genotype in p21 and suscep-
tibility to lung cancer demonstrated that Arg carriers had 
a higher risk of lung cancer (adjusted OR 1.38; 95% CI 
0.99–2.03, Table 2). Stratification for gender showed that 
men who were Arg carriers had an increased risk of lung 
cancer (adjusted OR 1.53; 95% CI 1.04–2.23). Because 
a statistically significant risk was found in men, and we 
had small numbers of women in our study populations, 
we focused on a stratified analysis only in men. Men who 
were Arg carriers and younger than 55 years had a two-fold 
increased risk of developing lung cancer (adjusted OR 2.35; 
95% CI 1.00–5.51). According to smoking status, we found 
that carrying the Arg allele increased the risk of lung cancer 
in ever smokers (adjusted OR 1.75; 95% CI 1.21–2.54). This 
risk was particularly strong in current smokers (adjusted OR 
2.23; 95% CI 1.24–4.02).
According to histological subtype, the p21 Arg allele 
polymorphism was associated with a higher risk of lung can-
cer in patients with small cell carcinoma (adjusted OR 2.11; 
95% CI 1.15–3.86) and squamous cell carcinoma (adjusted 
OR 1.39; 95% CI 0.86–2.26). According to occupation 
(list A), there was no higher risk of lung cancer in people 
who had an occupation included in list A (adjusted OR 1.66; 
95% CI 0.87–3.17, Table 4).
The frequency of the p53 Arg72Pro allele was 0.24 in 
cases and 0.27 in controls. This polymorphism was in Hardy-
Weinberg equilibrium (χ2 HW = 0.03; P = 0.872). There was 
no increase in risk of lung cancer for people harboring the 
p53 Arg72Pro allele (adjusted OR 1.19; 95% CI 0.91–1.54) 
(Table 3).
Stratified analysis of the Arg72Pro polymorphism did 
not show a higher risk in males (adjusted OR 1.17; 95% 
CI 0.88–1.53) for carriers of the Arg72Pro polymorphism. 
According to age, there was no increased risk in any of the 
three groups. Taking into account smoking status, the ever 
smoker group showed a higher risk of lung cancer (adjusted 
OR 1.43; 95% CI 1.09–1.86). No association between this 
polymorphism and increased risk of lung cancer stratified by 
histological type or occupation was observed (Table 5).
Combined analysis of p21 Ser31Arg  
and p53 Arg72Pro polymorphisms
Because p21 expression is regulated by p53, we investi-
gated the combined effect of subjects harboring both risk 
alleles, ie, p21 Ser31Arg and p53 Arg72Pro, using Ser/Ser 
homozygotes in p21 and Arg/Arg homozygotes in p53 as 
references. We considered moderate-risk individuals to be 
those with at least one risk allele (ie, Arg carriers of p21 
and Arg/Arg homozygotes of p53 or Pro carriers of p53 and 
Ser/Ser carriers of p21), and high-risk individuals to be those 
who carried an Arg allele of p21 and a Pro allele of p53, as 
shown in Table 6.
According to gender stratification, our results are consis-
tent with those previously described. Men with a high-risk 
genotype showed an increased risk of developing lung cancer 
(adjusted OR 2.29; 95% CI 1.21–4.32). Because males com-
prised the statistically significant risk group, we performed 
the stratified analysis in men only.
Those with a high-risk genotype had an increased risk 
of developing lung cancer while young, with individuals 
Table 2 Genotype distribution of p21 Ser31Arg polymorphism and adjusted odds ratio for lung cancer
Genotype p21 Ser31Arg Cases n (%) Controls n (%) Crude OR Adjusted OR (95% CI)a
Ser/Ser 565 (83.70) 589 (87.26) Reference Reference
Ser/Arg 107 (15.85) 88 (12.26) 1.39 1.42 (0.99–2.03)
Arg/Arg 3 (0.44) 6 (0.89) 0.52 0.59 (0.09–4.07)
Arg carriers 110 (16.30) 86 (12.74) 1.33 1.38 (0.97–1.96)
Arg allele frequency 0.08 0.07
Note: aAdjusted for age, gender, pack-years, familial history of lung cancer, and occupation (list A).
Abbreviations: CI, confidence interval; OR, odds ratio.
Table 3 Genotype distribution of p53 Arg72Pro polymorphism and adjusted odds ratio for lung cancer
Genotype p53 Arg72Pro Cases, n (%) Controls, n (%) Crude OR Adjusted OR (95% CI)a
Ser/Ser 341 (52.38) 318 (58.03) Reference Reference
Ser/Arg 267 (41.01) 198 (36.13) 1.26 1.16 (0.88–1.53)
Arg/Arg 43 (6.61) 32 (5.84) 1.25 0.59 (0.78–2.32)
Arg carriers 310 (47.62) 230 (41.97) 1.26 1.38 (0.91–1.54)
Pro allele frequency 0.27 0.24
Note: aAdjusted for age, gender, pack-years, familial history of lung cancer, and occupation (list A).
Abbreviations: CI, confidence interval; OR, odds ratio.
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younger than 55 years having a four-fold increased risk 
(adjusted OR 4.02; 95% CI 0.91–17.79). Stratification for 
smoking status revealed a higher risk for ever smokers 
(adjusted OR 3.61; 95% CI 1.80–7.22) and especially for 
current smokers (adjusted OR 4.25; 95% CI 1.41–12.82). 
Regarding histological type, we found that those with the 
high-risk genotype showed an increased risk of developing 
squamous cell carcinoma (adjusted OR 2.59; 95% CI 1.18–
5.69) and a four-fold increased risk of small cell carcinoma 
(adjusted OR 4.33; 95% CI 1.70–11.25).
Discussion
In the current study, we did not find a statistically significant 
association between the p21 Ser31Arg polymorphism and 
increased susceptibility to developing lung cancer in cases 
or controls. Nevertheless, it seems that the Arg allele may be 
related to an increased risk of lung cancer in men younger 
than 55 years and in those who smoke. The Arg allele may 
also increase the risk of small cell carcinoma. These results 
suggest that polymorphic variants may be less efficient and, 
thus, the capacity for cell cycle control by the p21 variant is 
limited compared with the wild-type protein.
With regard to the combined analysis of Ser31Arg and 
Arg72Pro polymorphisms, the results reported here are in 
agreement with those obtained for p21 Ser31Arg; in men 
who are carriers of risk alleles (ie, p21 Arg-carriers and p53 
Pro carriers), there is an increased risk of lung cancer. This 
risk has been particularly noted in men younger than 55 years 
who smoke, and is more likely to result in squamous cell 
carcinoma or small cell carcinoma.
We focused on the male population because the histologi-
cal distribution was different between men and women. The 
most common tumor observed in males was squamous cell 
carcinoma and in women was adenocarcinoma. Furthermore, 
in our study population, there were limited numbers of 
women.
In our study, the frequency of the Arg allele was similar 
to that obtained in other studies performed in Caucasian 
populations. Our frequency of Arg allele carriers was 0.07, 
which is similar to that reported by Koopmann et al (0.085),25 
Su et al (0.09),20 and Popanda et al (0.07)26 in European 
populations.
Thus, by analyzing the whole population, we show an 
increased risk of lung cancer in men who were Arg carriers. 
Presence of the Arg allele increased the risk in men younger 
than 55 years. The same was true for smokers but, interest-
ingly, smokers who consumed less than 37 pack-years had a 
higher risk than heavy smokers. Thus, our data suggest that 
men who are Arg carriers develop cancer prematurely and 
with a smaller burden of external aggression, so this poly-
morphism may be a promising risk marker for this population 
group. The Arg allele frequency varies by ethnicity, so the 
genetic effects of p21 Ser31Arg polymorphisms might be 
different in distinct ethnic groups.
Because p21 plays a fundamental role in inhibiting cell 
cycle progression and apoptosis, and can inhibit tumor 
progression,27 genetic polymorphisms may alter the normal 
function of the protein and lead to an increased risk of lung 
cancer. The association between Ser31Arg polymorphisms 
and risk of developing different kinds of tumors has been ana-
lyzed in several studies, with disparate results.  Specifically, 
the presence of the Ser allele is associated with an increased 
risk of cervical and endometrial cancer,28,29 and the presence 
of the Arg allele has been correlated with a higher risk of 
breast cancer and squamous cell carcinoma of the head and 
neck.30,31
Although a clear difference has not been demonstrated 
in p21 protein function (cyclin-dependent kinase inhibitor or 
cell cycle suppressor) due to the presence of the Arg allele, 
the possibility cannot be excluded that the Arg allele might 
affect other processes in which p21 is involved, either p53-
dependent or related to other transcription factors.18 Thus, 
there may exist post-transcriptional or translational modifica-
tions that also alter the protein function.
Lung cancer studies have yielded contradictory results. 
In a Swedish study involving 144 cases and 761 controls, 
the risk of lung cancer associated with the Arg allele was 
increased (OR 1.7).18 Unlike our results, which point to an 
increased risk in Arg carriers, no association was found 
in a study of 155 cases and 189 controls in a Taiwanese 
population.19 Su et al did not find an association between this 
polymorphism and lung cancer risk in a Caucasian population 
of 1220 cases and 1069 controls either, but there was a slight 
decrease in risk for former smokers (OR 0.69).20 Choi et al 
demonstrated that Ser31Arg polymorphisms appeared to be 
in linkage disequilibrium with IVS2 + 16G . C (rs3176352) 
in a Korean population. Analysis of this haplotype for lung 
cancer susceptibility demonstrated a protective effect which 
was dependent on the number of variant alleles.32
A negative correlation between lymph node status and 
p21 expression was observed in a recent study, suggesting 
a possible role for p21 in the progression of nonsmall cell 
lung cancer. In the same study, a statistically significant cor-
relation was found between expression and survival.33 Our 
results differ from those obtained in other studies of lung, 
endometrial, and gastric cancers, for which the Ser allele 
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of p21 appears to confer increased risk.26,29,34 This may be 
explained by the difference in allele frequencies between 
European and Asian populations.
Large sample sizes from a homogeneous population 
with similar ancestry (802 cases and 718 controls) and high 
participation of eligible cases (rate 91.4%) are notable strengths 
in our study. Furthermore, all of our cases were confirmed 
pathologically. A potential limitation could be the use of 
hospital-based controls. Because information on confounding 
variables was obtained retrospectively, recall bias could be 
present. However, estimators obtained for the most important 
confounding variable (tobacco) were in line with the literature. 
Residual confounding cannot be excluded, because these data 
could not be evaluated in the never smoked group, and the 
number of nonsmoker cases was limited. Moreover, given that 
the polymorphism frequency in our study was small, some strata 
had a small size, so the stratified analysis was limited.
Conclusion
The presence of both variant alleles (p21 Ser31Arg and 
p53 Arg72Pro) increased the risk of lung cancer in men, espe-
cially those younger than 55 years and in those who smoked. 
Therefore, these polymorphisms may have a potential role as 
markers of susceptibility for these groups of people.
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